

## FORM 7

### MONTHLY PROGRESS REPORT

Name of Listed Issuer: EGF Theramed Health Corp. (the "Issuer").

Trading Symbol: TMED

Number of Outstanding Listed Securities: 18,452,766

Date: August 12, 2020

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

#### **General Instructions**

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

---

### FORM 7 – MONTHLY PROGRESS REPORT

January 2015

Page 1

## Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

**The Company has announced on July 9, 2020, has noted that Global Green Parrot Laboratories Inc. has entered into a memorandum of understanding with Greenfield Global Projects Inc. Greenfield is a private company with extensive cannabis related projects in Jamaica and corporate offices in Vancouver, B.C. Green Parrot Labs Corp., a joint venture partner in which the Company holds a 40% equity interest, holds a 70% equity interest in GGP.**

**The MOU sets out the proposed terms and conditions for a medical tourism treatment center to be located in Jamaica, initially for the treatment of irritable bowel disorder ("IBD"). The medical tourism treatment center will be operated by GGP but under the licensed auspices of Greenfield under a lease arrangement. In addition, GGP will have the ability to lease laboratory space from Greenfield, when able, for the research and production of brewing technologies and related technology using biosynthesis unique to GGP.**

**The proposed transaction will be based upon the following terms and conditions:**

**GGP will incur all expenses related to the establishment of an IBD treatment facility in Jamaica, with the intention of operating under a sub-lease from Greenfield, or with the use of licensing and facilities provided by Greenfield.**

**GGP intends to operate the facility using physicians licensed in Jamaica and trained and supervised by GGP. GGP will insure patients and indemnify Greenfield, at its cost.**

**GGP will pay Greenfield a royalty of 5% of gross costs per procedure performed at the IBD center.**

**GGP will also enter into a lease for the treatment center to be housed when ready but will have the ability to offer IBD center treatments at an independent location, until the Greenfield facilities are operative.**

**GGP will also look to enter into leased laboratory facilities for biosynthesis research and limited production of ingredients for the brewing Industry. GGP intends to use its**

licensed technology to produce non-competing products and will pay a 4% royalty to Greenfield for production grade ingredients that are resold.

Completion of the proposed transaction will be subject to the parties entering into formal definitive agreements between GGP and Greenfield or their legal assignees containing the terms and conditions specified in the MOU and other market standard conditions, representations, warranties, covenants, indemnities of the parties. The proposed transaction is subject to a 30 day due diligence period, followed by an additional 45 days to enter into definitive agreements.

On July 9, 2020, the Company announced that it will rely on the temporary relief granted pursuant to British Columbia Instrument 51-517 (Temporary Exemption from Certain Corporate Finance Requirements with Deadlines During the Period from June 2 to August 31, 2020) in respect of the filing of business acquisition reports (BAR) for its acquisition of a 30-per-cent equity interest in Pharmadelic Labs Corp. on May 6, 2020, and its acquisition of a 40-per-cent equity interest in Green Parrot Labs Corp. on May 25, 2020.

2. Provide a general overview and discussion of the activities of management.
3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

**The Issuer did not develop any new products or services during the month of July 2020.**

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

**The Issuer did not discontinue any products or services during the month of July 2020.**

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

---

## FORM 7 – MONTHLY PROGRESS REPORT

January 2015

**The Issuer did not enter into any new business relationships during the month of July 2020.**

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

**The Issuer did not have expiry or termination of any contracts or agreements during the month of July 2020.**

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

**Please refer to #1**

8. Describe the acquisition of new customers or loss of customers.

**The Issuer did not acquire or lose any customers during the month of July 2020.**

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

**Please refer to #1**

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

**The Issuer did not hire, terminate or lay-off any employees during the month of July 2020.**

11. Report on any labour disputes and resolutions of those disputes if applicable.

**The Issuer had no labour disputes as of July 2020.**

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

**The Issuer is not a party to any legal proceedings.**

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

**The Issuer did not incur or repay any indebtedness during July 2020.**

14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds <sup>(1)</sup>

*(1) State aggregate proceeds and intended allocation of proceeds.*

15. Provide details of any loans to or by Related Persons.

**The Issuer did not receive/make any loans from/to Related Persons during July 2020.**

16. Provide details of any changes in directors, officers or committee members.

**Refer to #1**

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

**The Issuer is not aware of any trends, uncertainties, demands, commitments or events which are reasonably likely to have a material effect upon its revenues, income from continuing operations, profitability, liquidity or capital resources or that would cause reported financial information not necessarily to be indicative of future operating results or financial condition.**

## Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: August 12, 2020.

**Usama Chaudhry**

Name of Director or Senior Officer

**/s/ Usama Chaudhry**

Signature

**CFO**

Official Capacity

<b>Issuer Details</b>		For Month	Date of Report
Name of Issuer		Ended	YY/MM/D
EGF Theramed Health Corp.		July 2020	2020/08/12
Issuer Address			
5728 East Boulevard			
City/Province/Postal Code		Issuer Fax No.	Issuer Telephone No.
Vancouver, BC, V6M 4M4			(604) 780-3311
Contact Name		Contact Position	Contact Telephone No.
Usama Chaudhry		CFO	(604) 780-3311
Contact Email Address		Web Site Address	
<a href="mailto:theramedhealthcorp@gmail.com">theramedhealthcorp@gmail.com</a>		<a href="http://www.theramedhealthcorp.com">www.theramedhealthcorp.com</a>	

---

**FORM 7 – MONTHLY PROGRESS REPORT**

January 2015